What makes Stayble unique

Stayble Therapeutics is dedicated to developing an effective treatment option for both degenerative disc disease (DDD) and lumbar disc herniation (LDH) using the company's drug candidate, STA363. This minimally invasive treatment offers an efficient and simple solution for the millions of individuals suffering from chronic back and leg pain, where pain medication or physical therapy have proven ineffective.

Read more

Get to know Stayble

Latest press releases

November 14, 2023 Regulatorisk

Correction: Stayble Therapeutics publishes interim report for the third quarter of 2023

Republishes with MAR text in the press release. No changes have been made to the press release or the attached report. Stayble Therapeutics AB ("Stayble"...

Read more| Download PDF
November 14, 2023 Regulatorisk

Stayble Therapeutics publishes interim report for the third quarter of 2023

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its quarterly report for the third quarter of 2023. The report is available as an attached...

Read more| Download PDF

Financial reports

Interim report Q3 2023 (SE)Download
Half-year report 2023 (SE)Download
INTERIM REPORT Q1 2023 (SE)Download
Annual report 2022 (SE)Download

What makes stayble unique?

By using STA363 in two separate projects targeting DDD and LDH respectively, Stayble has advanced to a position at the forefront of injection-based, minimally invasive treatments for chronic back and leg pain. As Stayble has developed successfully, the Company is competing to become the market leader in second-line therapies for pain caused by degeneration and hernia.

About Stayble

One candidate- two treatments against chronic back and leg pain

About Stayble

Treatment of degenerative disc disease (DDD)

Stayble currently has one lead R&D project, which is a one-time injectionbased treatment (STA363) for patients suffering from degenerative disc disease and is currently being evaluated in an fully recruited ongoing clinical phase 2b trial.

DDD candidate

Treatment of lumbar disc herniation (LDH)

We recently seized the opportunity to launch the development of a second project, based on the same candidate (STA363), which aims to target patients suffering from unresolved herniated discs.

LDH Candidate

Invest in the future treatment of chronic back and leg pain

Stayble is listed on Nasdaq First North under the ticker STABL. You will find all relevant information on the Stayble share in our Investors section.

Investors

Bridging the therapeutic gap

The majority of patients suffering from degenerative disc disease and unresolved disc hernia are not helped by conservative treatment with analgesics and physiotherapy. With no long term treatment options than surgery most of these patient continues to suffer without improvment.

Stayble’s product STA363 will bridge the gap between conservative and radical therapy to the benefit of millions of patients presently left on their own to cope with sustained and disabling pain.

About Stayble